结核分枝杆菌对吡嗪酰胺耐药的相关基因及耐药机制研究进展

doi:10.19982/j.issn.1000-6621.20210511

中国防痨杂志 ›› 2022, Vol. 44 ›› Issue (1): 102-105.doi: 10.19982/j.issn.1000-6621.20210511

结核分枝杆菌对吡嗪酰胺耐药的相关基因及耐药机制研究进展

周婷婷¹^,², 郑小曼², 欧阳净², 鲁雁秋², 陈耀凯¹^,³()

¹西南大学医学研究院,重庆 400715
²重庆市公共卫生医疗救治中心科教科,重庆 400036
³重庆市公共卫生医疗救治中心感染科,重庆 400036

收稿日期:2021-08-24 出版日期:2022-01-10 发布日期:2021-12-29
通信作者: 陈耀凯 E-mail:yaokaichen@hotmail.com
基金资助:
重庆市卫生计生委中医药科技项目(ZY201801003);重庆市科卫联合医学科研项目(2020GDRC004);重庆市科技局人才项目(cstc2021ycjh-bgzxm0275)

Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide

ZHOU Ting-ting¹^,², ZHENG Xiao-man², OUYANG Jing², LU Yan-qiu², CHEN Yao-kai¹^,³()

¹Southwest University Medical Research Institute, Chongqing 400715, China
²Science and Education Division, Chongqing Public Health Medical Center,Chongqing 400036,China
³Infectious Disease Department, Chongqing Public Health Medical Center,Chongqing 400036,China

Received:2021-08-24 Online:2022-01-10 Published:2021-12-29
Contact: CHEN Yao-kai E-mail:yaokaichen@hotmail.com
Supported by:
The Traditional Chinese Medicine Research Project of Chongqing Health Commission(ZY201801003);Medical Research Projects of Chongqing Municipal Science and Technology Bureau and Health Commission(2020GDRC004);Chongqing Talent Cultivation Program(cstc2021ycjh-bgzxm0275)

摘要/Abstract

摘要：

吡嗪酰胺是结核病最重要的一线治疗药物之一,但结核分枝杆菌对其耐药性在逐年增长,目前对于结核分枝杆菌吡嗪酰胺的耐药基因的分子机制尚无定论。作者对结核分枝杆菌吡嗪酰胺的相关耐药基因pncA、rpsA、panD、fadD2及FAS-I的研究进展进行综述。

关键词: 分枝杆菌,结核, 吡嗪酰胺, 抗药性, 基因

Abstract:

Pyrazinamide is one of the most important first-line therapeutic drugs for tuberculosis, but the resistance of Mycobacterium tuberculosis to this drug is increasing year by year. At present, molecular mechanisms and drug resistance related genes of pyrazinamide is still inconclusive. The authors review research progress of pyrazinamide resistance related genes, including pncA, rpsA, panD, fadD2 and FAS-I.

Key words: Mycobacterium tuberculosis, Pyrazinamide, Drug resistance, Genes

中图分类号:

R52
R446.5

周婷婷, 郑小曼, 欧阳净, 鲁雁秋, 陈耀凯. 结核分枝杆菌对吡嗪酰胺耐药的相关基因及耐药机制研究进展[J]. 中国防痨杂志, 2022, 44(1): 102-105. doi: 10.19982/j.issn.1000-6621.20210511

ZHOU Ting-ting, ZHENG Xiao-man, OUYANG Jing, LU Yan-qiu, CHEN Yao-kai. Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide[J]. Chinese Journal of Antituberculosis, 2022, 44(1): 102-105. doi: 10.19982/j.issn.1000-6621.20210511

参考文献 29

[1]	World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization, 2021.
[2]	Kempker RR, Heinrichs MT, Nikolaishvili K, et al. Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2017, 61(6):e00226-17. doi: 10.1128/AAC.00226-17.0. doi: 10.1128/AAC.00226-17.0
[3]	Singh R, Dwivedi SP, Gaharwar US, et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol, 2020, 128(6):1547-1567. doi: 10.1111/jam.14478. doi: 10.1111/jam.14478 pmid: 31595643
[4]	Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis, 2019, 19(1):116. doi: 10.1186/s12879-019-3764-2. doi: 10.1186/s12879-019-3764-2 URL
[5]	Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resis-tant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect, 2018, 24(9):e1011-1016. doi: 10.1016/j.cmi.2017.12.012. doi: 10.1016/j.cmi.2017.12.012
[6]	Dudley MZ, Sheen P, Gilman RH, et al. Detecting Mutations in the Mycobacterium tuberculosis Pyrazinamidase Gene pncA to Improve Infection Control and Decrease Drug Resistance Rates in Human Immunodeficiency Virus Coinfection. Am J Trop Med Hyg, 2016, 95(6):1239-1246. doi: 10.4269/ajtmh.15-0711. doi: 10.4269/ajtmh.15-0711 URL
[7]	Yadon AN, Maharaj K, Adamson JH, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun, 2017, 8(1):588. doi: 10.1038/s41467-017-00721-2. doi: 10.1038/s41467-017-00721-2 pmid: 28928454
[8]	Li K, Yang Z, Gu J, et al. Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China. Front Microbiol, 2020, 11:594171. doi: 10.3389/fmicb.2020.594171. doi: 10.3389/fmicb.2020.594171
[9]	Ei PW, Mon AS, Htwe MM, et al. Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis (Edinb), 2020, 125:102013. doi: 10.1016/j.tube.2020.102013. doi: 10.1016/j.tube.2020.102013
[10]	Naluyange R, Mboowa G, Komakech K, et al. High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda. PLoS One, 2020, 15(5):e0232543. doi: 10.1371/journal.pone.0232543. doi: 10.1371/journal.pone.0232543
[11]	Wu X, Lu W, Shao Y, et al. PncA gene mutations in reporting pyrazinamide resistance among the MDR-TB suspects. Infect Genet Evol, 2019, 72:147-150. doi: 10.1016/j.meegid.2018.11.012. doi: 10.1016/j.meegid.2018.11.012 URL
[12]	Katale BZ, Mbelele PM, Lema NA, et al. Whole genome sequencing of Mycobacterium tuberculosis isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania. BMC Genomics, 2020, 21(1):174. doi: 10.1186/s12864-020-6577-1. doi: 10.1186/s12864-020-6577-1 URL
[13]	Aggarwal M, Singh A, Grover S, et al. Role of pncA gene mutations W68R and W68G in pyrazinamide resistance. J Cell Biochem, 2018, 119(3):2567-2578. doi: 10.1002/jcb.26420. doi: 10.1002/jcb.26420 pmid: 28980723
[14]	Shi J, Su R, Zheng D, et al. Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province. Infect Drug Resist, 2020, 13:2929-2941. doi: 10.2147/IDR.S260161. doi: 10.2147/IDR.S260161 URL
[15]	Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 2011, 333(6049):1630-1632. doi: 10.1126/science.1208813. doi: 10.1126/science.1208813 URL
[16]	Dillon NA, Peterson ND, Feaga HA, et al. Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA. Sci Rep, 2017, 7(1):6135. doi: 10.1038/s41598-017-06415-5. doi: 10.1038/s41598-017-06415-5 URL
[17]	Vallejos-Sanchez K, Lopez JM, Antiparra R, et al. Mycobacterium tuberculosis ribosomal protein S1 (RpsA) and variants with truncated C-terminal end show absence of interaction with pyrazinoic acid. Sci Rep, 2020, 10(1):8356. doi: 10.1038/s41598-020-65173-z. doi: 10.1038/s41598-020-65173-z pmid: 32433489
[18]	Gopal P, Nartey W, Ragunathan P, et al. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. ACS Infect Dis, 2017, 3(11):807-819. doi: 10.1021/acsinfecdis.7b00079. doi: 10.1021/acsinfecdis.7b00079 URL
[19]	Zhang S, Chen J, Shi W, et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect, 2013, 2(6):e34. doi: 10.1038/emi.2013.38. doi: 10.1038/emi.2013.38
[20]	Shi W, Chen J, Feng J, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect, 2014, 3(8):e58. doi: 10.1038/emi.2014.61. doi: 10.1038/emi.2014.61
[21]	Gopal P, Sarathy JP, Yee M, et al. Pyrazinamide triggers degradation of its target aspartate decarboxylase. Nat Commun, 2020, 11(1):1661. doi: 10.1038/s41467-020-15516-1. doi: 10.1038/s41467-020-15516-1 URL
[22]	Sun Q, Li X, Perez LM, et al. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD. Nat Commun, 2020, 11(1):339. doi: 10.1038/s41467-019-14238-3. doi: 10.1038/s41467-019-14238-3 URL
[23]	Pandey B, Grover S, Tyagi C, et al. Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis. Gene, 2016, 581(1):31-42. doi: 10.1016/j.gene.2016.01.024. doi: 10.1016/j.gene.2016.01.024 URL
[24]	Rosen BC, Dillon NA, Peterson ND, et al. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2017, 61(2):e02130-16. doi: 10.1128/AAC.02130-16. doi: 10.1128/AAC.02130-16
[25]	Elad N, Baron S, Peleg Y, et al. Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3Å resolution. Nat Commun, 2018, 9(1):3886. doi: 10.1038/s41467-018-06440-6. doi: 10.1038/s41467-018-06440-6 URL
[26]	Ahmady A, Poolad T, Rafee P, et al. Study of pyrazinamidase structural changes in pyrazinamide resistant and susceptible isolates of Mycobacterium tuberculosis. Tuberk Toraks, 2013, 61(2):110-114. doi: 10.5578/tt.3888. doi: 10.5578/tt.3888 URL
[27]	Sayahi H, Pugliese KM, Zimhony O, et al. Analogs of the antituberculous agent pyrazinamide are competitive inhibitors of NADPH binding to M.tuberculosis fatty acid synthase I. Chem Biodivers, 2012, 9(11):2582-2596. doi: 10.1002/cbdv.201200291. doi: 10.1002/cbdv.201200291 URL
[28]	Werngren J, Alm E, Mansjo M. Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That? J Clin Microbiol, 2017, 55(6):1920-1927. doi: 10.1128/JCM.02532-16. doi: 10.1128/JCM.02532-16 pmid: 28404681
[29]	Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resis-tance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol, 2014 52(1):291-297. doi: 10.1128/JCM.01903-13. doi: 10.1128/JCM.01903-13 URL

结核分枝杆菌对吡嗪酰胺耐药的相关基因及耐药机制研究进展

Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	孙晴, 廖鑫磊, 王晨倩, 姜广路, 董玲玲, 王芬, 赵立平, 黄海荣, 王桂荣. GeneXpert MTB/RIF阳性RNA聚合酶β亚基基因突变的结核病患者中利福平耐药决定区突变特征研究[J]. 中国防痨杂志, 2022, 44(4): 349-353.
[2]	田丽, 周伟, 黄星, 吴显伟, 张惠勇, 鹿振辉, 张少言. 中国异烟肼耐药结核分枝杆菌基因突变特征分析[J]. 中国防痨杂志, 2022, 44(4): 354-361.
[3]	解冰洁, 靳飞, 张俊丽, 徐华, 陈海峰, 张会民. 河北省2020年结核病耐药监测结果分析[J]. 中国防痨杂志, 2022, 44(4): 403-408.
[4]	李东硕, 王彬, 陆宇, 徐建. 结核分枝杆菌膜蛋白MmpS5-MmpL5的表达及功能研究[J]. 中国防痨杂志, 2022, 44(3): 227-233.
[5]	岳英, 黄婷婷, 任斐, 马进宝, 漆沄. 先天性耐药结核病一例并文献复习[J]. 中国防痨杂志, 2022, 44(3): 252-257.
[6]	王少华, 赵国连, 王佩, 谈小文, 崔晓利, 康磊, 党丽云. 结核分枝杆菌利福平基因型药敏和表型药敏检测结果不一致原因分析[J]. 中国防痨杂志, 2022, 44(2): 169-173.
[7]	王威, 叶一农, 林东子, 钟倩红, 黄飞, 杜芳芳, 成诗明, 周杰, 张锡林, 钟球. 2011—2020年广东省佛山市利福平耐药结核病流行特征分析[J]. 中国防痨杂志, 2022, 44(2): 187-192.
[8]	中国防痨协会中国疾病预防控制中心结核病预防控制中心, 中国疾病预防控制中心结核病预防控制中心. Pretomanid (PA-824)治疗耐多药结核病的应用建议[J]. 中国防痨杂志, 2022, 44(1): 38-44.
[9]	首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所, 中国防痨协会《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版)[J]. 中国防痨杂志, 2021, 43(9): 859-866.
[10]	周文强, 张爽, 初乃惠. 耐药肺结核全口服治疗方案研究的现状和展望[J]. 中国防痨杂志, 2021, 43(9): 879-882.
[11]	石文卉, 初乃惠. 耐药肺结核患者氟喹诺酮类药物耐药情况及影响因素[J]. 中国防痨杂志, 2021, 43(9): 905-909.
[12]	林建, 林淑芳, 戴志松, 赵永, 周银发, 张添林, 魏淑贞. 2016—2019年福建省结核病耐药监测结果分析[J]. 中国防痨杂志, 2021, 43(9): 924-928.
[13]	于霞, 任汝颜, 文舒安, 梁倩, 董玲玲, 黄海荣. 13种抗生素对快生长分枝杆菌的体外抑菌效果评价[J]. 中国防痨杂志, 2021, 43(9): 947-951.
[14]	马婷婷, 任斐, 马进宝, 杨翰. 异烟肼耐药肺结核患者对丙硫异烟胺和对氨基水杨酸的耐药情况分析[J]. 中国防痨杂志, 2021, 43(9): 961-964.
[15]	夏辉, 赵雁林. 世界卫生组织《关于更新使用结核分枝杆菌及其耐药性核酸扩增检测技术的建议》的启示[J]. 中国防痨杂志, 2021, 43(8): 761-765.